CD200
OX-2 membrane glycoprotein
As of the edition of 20 October 2026, CD200 (OX-2 membrane glycoprotein, UniProt P41217) has 1 drug tested at it and 2 companies on the list, 2 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P41217
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- At a membrane
- Disease areas
- Cancer; Blood and lymph; Heart and blood vessels; Immune system
- Registered trials of its drugs
- 3
Drugs at this target
| Status | Count |
|---|---|
| Stopped | 1 |
| Total | 1 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Samalizumab | Stopped | Phase 3 | none listed |
1 of 1 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| AstraZeneca | Route A |
| Beat AML | Route A |
The other 0 companies at CD200
In the product2 companies in all; 0 are not named here, and no score is.
See the 2 companies at CD200, ranked, with the facts behind eachRequest access. Nothing is shown until you do.